Medyria’s mission is to make minimally invasive cardiovascular procedures more effective, faster, and safer. Today, such interventions are visualized using x-ray and contrast-dye, both of which can lead to severe health complications. Medyria has developed a catheter positioning system with the potential to significantly reduce the use of x-ray and contrast dye.
Location: Switzerland
Total raised: $12.56M
Investors 5
| Date | Name | Website |
| - | Verve Vent... | verve.vc |
| - | Venture Ki... | venturekic... |
| - | EFI Lake G... | lakegeneva... |
| 24.02.2023 | VentureLab | venturelab... |
| - | StartAngel... | startangel... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 27.07.2026 | - | $4.29M | - |
| 17.07.2025 | - | $1.87M | - |
| 11.01.2023 | - | $4.01M | StartAngel... |
| 30.01.2015 | Series A | $2.39M | - |
Mentions in press and media 25
| Date | Title | Description |
| 29.07.2026 | Medyria Secures Major Funding for US Cardiology Market Entry | Swiss medical technology innovator Medyria has closed a significant CHF 3.5 million investment round. This capital injection primarily targets aggressive US market expansion. Medyria, founded in 2012, specializes in groundbreaking invasive ... |
| 27.07.2026 | Medyria secures CHF 3.5 million to advance US expansion | Founded in 2012 and based at Technopark Winterthur, Medyria develops blood-flow velocity sensors and catheter technologies for coronary diagnosis. A Venture Kick, Venture Leaders, and Top100 Swiss Startup alumnus, the company's flagship pro... |
| 24.07.2026 | Medyria raises CHF 3.5 million | Medyria, founded in 2012 and headquartered at the Technopark Winterthur, is a Swiss medical technology pioneer specializing in the advancement of invasive coronary diagnostics. The company develops blood-flow-velocity sensors and catheter ... |
| 17.07.2025 | Medyria secures CHF 1.5M to advance PyCath development and expand globally | The CHF 1.5 million round, led by Buenavista and its managing partner Bibi Sattar Marques, will allow Medyria to move forward with key milestones for its PyCath catheter system. The funding will support the first-in-human clinical study and... |
| 16.07.2025 | Medyria secures CHF 1.5 million to accelerate development of its medical device | The secured funds will be strategically utilized to accelerate the further development of the PyCath system. A key focus will be on initiating the first-in-human clinical experience, a critical milestone that will validate the system's eff... |
| 09.05.2025 | Milestones achievements for life sciences startups | Nouscom, a clinical-stage biotech company developing next-generation neoantigen-targeted off-the-shelf and personalized cancer immunotherapies, has presented the safety and immunogenicity results from a Phase Ib/II study evaluating NOUS-20... |
| 27.11.2023 | Sparks IPO Academy prepares new cohort for next move | |
| 11.01.2023 | Medyria raises CHF3.7 million to bring its diagnostic device closer to market entry | |
| 11.01.2023 | Medyria secures CHF 3.7 million to bring novel diagnostic device closer to market entry | Medyria AG is a Medtech company leader in blood flow velocity sensing. Based in Winterthur, the startup recently launched the development of PyCath, a novel microcatheter for the invasive diagnosis of ischemic heart conditions, including ob... |
| 11.01.2023 | Medyria secures CHF 3.7 million to bring novel diagnostic device closer to market entry | Medyria secures CHF 3.7 million to bring novel diagnostic device closer to market entry 11.01.2023 09:15, Morgane Ghilardi linkedIn facebook twitter instagram youtube --> The Series B financing is a CHF 3.7 million equity investment from... |
Show more